Nlumn

Nlumn is a biotechnology company focused on the discovery and development of small molecule therapeutics that target protein-protein interactions (PPIs). Founded by Dr. Peter S. Kim, former President of Merck Research Labs, the company utilizes a proprietary platform to identify and inhibit PPIs that have historically been considered undruggable. Nlumn's approach integrates advanced structural biology, computational modeling, and specialized screening techniques to create high-affinity small molecules. The company is currently in the pre-clinical stage, with a primary focus on therapeutic areas such as oncology, immunology, and infectious diseases. Nlumn is backed by prominent life science investors, including Foresite Capital and GV, to advance its mission of drugging the dark proteome.